Drugs · Entity Annotation Prototype (beta)

6articles mentioning drugs

17drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: pMDIs ×

pMDIs

This drug is selected. Its supporting articles are shown below.

pMDIs6

Articles mentioning pMDIs

6 articles · page 1 of 1

Inhaler use and their carbon footprint in Germany: a 10-year analysis (2013–2022)

bmjresp · abstract · 2025-10-22 · 5 matching annotations

90.3%

pMDIs pMDI soft mist inhalers chronic obstructive pulmonary disease asthma statutory health insurances

…sment-derived CF values were calculated for four inhaler types: pMDIs with hydrofluorocarbon (HFC)-134a, pMDIs with HFC-227ea, dry po…

Modelling the climate impact of inhalers and mitigation strategies: a population-based study in British Columbia, Canada (2015–2032)

bmjresp · abstract · 2025-10-02 · 5 matching annotations

86.2%

pMDIs SMIs pMDI DPIs respiratory disease

…uilding on these benefits, our analysis shows that substituting pMDIs with lower-emission inhalers, when guided by policy and clinica…

The environmental impact of inhalers: a framework for sustainable prescription practices in Spain

ejhpharm · abstract · 2025-10-24 · 4 matching annotations

90.2%

pMDIs inhalers DPIs

…ces to reduce healthcare’s carbon footprint. Transitioning from pMDIs to DPIs when clinically indicated offers considerable environme…

Air pollution, inhaled therapy and COPD exacerbations in Yunlin, Taiwan: a 2016–2024 single-centre retrospective cohort with environmental and carbon-footprint analyses

bmjresp · abstract · 2025-12-17 · 1 matching annotations

76.2%

LAMAs SABAs LABAs LAMA LABA ICS SABA pMDIs COPD chronic obstructive pulmonary disease+3 more

…acting β2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and triple therapy (ICS/LABA/LAMA), on exacerbation rates and …

Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe

bmjresp · abstract · 2025-09-01 · 1 matching annotations

77.2%

SABA pMDI pMDI-based pMDI-related pMDIs EU

… therapy will potentially improve patient outcomes and decrease SABA over-reliance. Prioritising DPIs or soft mist inhalers when cli…

Inhaler sustainability in asthma and COPD care: a systematic review

bmjopen · abstract · 2025-07-25 · 1 matching annotations

76.1%

SABAs pMDIs Chronic Obstructive Pulmomary Disease asthma Cochrane Library COPD Scopus

… carbon footprints than pMDIs, with short-acting beta-agonists (SABAs) pMDIs having the highest emissions due to prescription, use pa…